Earnings Feed
Start Free
Home/Filings/4/0000911916-17-000083
4//SEC Filing

CoLucid Pharmaceuticals, Inc. 4

Accession 0000911916-17-000083

CIK 0001348649operating
View on SEC.govCompany Profile

Filed

Feb 28, 7:00 PM ET

Accepted

Mar 1, 12:30 PM ET

Size

14.5 KB

Accession

0000911916-17-000083

Insider Transaction Report

Form 4
Period: 2017-03-01
CoLucid Pharmaceuticals, Inc.CLCD
White Marvin L
Director
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$38.00/sh−997$37,886→ 0 total
    Exercise: $8.50Exp: 2026-01-04→ Common Stock (997 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$40.26/sh−8,897$358,193→ 0 total
    Exercise: $6.24Exp: 2026-05-10→ Common Stock (8,897 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$36.88/sh−1,630$60,114→ 0 total
    Exercise: $9.62Exp: 2026-07-01→ Common Stock (1,630 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$37.90/sh−6,577$249,268→ 0 total
    Exercise: $8.60Exp: 2025-07-09→ Common Stock (6,577 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$10.30/sh−453$4,666→ 0 total
    Exercise: $36.20Exp: 2027-01-03→ Common Stock (453 underlying)
Footnotes (2)
  • [F1]Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
  • [F2]Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.

Documents

1 file

Issuer

CoLucid Pharmaceuticals, Inc.

CIK 0001348649

→
Entity typeoperating

Related Parties

1
  • filerCIK 0001348649

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 12:30 PM ET
Size
14.5 KB
View on SEC.gov